Literature DB >> 15349768

Telomerase RNA deficiency in peripheral blood mononuclear cells in X-linked dyskeratosis congenita.

Judy M Y Wong1, Mouhammed J Kyasa, Laura Hutchins, Kathleen Collins.   

Abstract

Compromised renewal and eventual failure of the hematopoietic system in dyskeratosis congenita (DC) have been proposed to arise from a deficiency in telomerase function. Previously, cultured cell lines from patients with X-linked DC were shown to accumulate less telomerase RNA than cell lines from unaffected family members. Here, we report that telomerase RNA deficiency is also present in the circulating lymphocytes of DC patients. We have compared the accumulation levels of telomerase RNA and a panel of other small RNAs in peripheral blood mononuclear cells from an X-linked DC patient and an unaffected maternal carrier and similarly analyzed cultured lymphoblasts from an X-linked DC patient and maternal carrier in a second family. The DC-patient lymphoid cells show a specific defect in telomerase RNA accumulation with or without cell culture. Our findings support the clinical significance of telomerase deficiency and encourage the use of telomerase activation as a disease therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15349768     DOI: 10.1007/s00439-004-1178-7

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  31 in total

Review 1.  Biogenesis of small nucleolar ribonucleoproteins.

Authors:  Witold Filipowicz; Vanda Pogacić
Journal:  Curr Opin Cell Biol       Date:  2002-06       Impact factor: 8.382

2.  Subnuclear shuttling of human telomerase induced by transformation and DNA damage.

Authors:  Judy M Y Wong; Leonard Kusdra; Kathleen Collins
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

Review 3.  Dyskeratosis congenita.

Authors:  A Marrone; P J Mason
Journal:  Cell Mol Life Sci       Date:  2003-03       Impact factor: 9.261

Review 4.  Biochemical aspects of telomerase function.

Authors:  Lea Harrington
Journal:  Cancer Lett       Date:  2003-05-15       Impact factor: 8.679

5.  Targeted disruption of Dkc1, the gene mutated in X-linked dyskeratosis congenita, causes embryonic lethality in mice.

Authors:  Jun He; Sandra Navarrete; Murek Jasinski; Tom Vulliamy; Inderjeet Dokal; Monica Bessler; Philip J Mason
Journal:  Oncogene       Date:  2002-10-31       Impact factor: 9.867

Review 6.  Structure and biogenesis of small nucleolar RNAs acting as guides for ribosomal RNA modification.

Authors:  W Filipowicz; P Pelczar; V Pogacic; F Dragon
Journal:  Acta Biochim Pol       Date:  1999       Impact factor: 2.149

7.  Increased mortality rate and not impaired ribosomal biogenesis is responsible for proliferative defect in dyskeratosis congenita cell lines.

Authors:  Lorenzo Montanaro; Alessandra Chillà; Davide Trerè; Annalisa Pession; Marzia Govoni; Pier Luigi Tazzari; Massimo Derenzini
Journal:  J Invest Dermatol       Date:  2002-01       Impact factor: 8.551

8.  Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation.

Authors:  D Broccoli; L A Godley; L A Donehower; H E Varmus; T de Lange
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

9.  Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA.

Authors:  Patrick F Fogarty; Hiroki Yamaguchi; Adrian Wiestner; Gabriela M Baerlocher; Elaine Sloand; Weihua S Zeng; Elizabeth J Read; Peter M Lansdorp; Neal S Young
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

Review 10.  Evolving views of telomerase and cancer.

Authors:  Maria A Blasco; William C Hahn
Journal:  Trends Cell Biol       Date:  2003-06       Impact factor: 20.808

View more
  30 in total

Review 1.  The genetics of dyskeratosis congenita.

Authors:  Philip J Mason; Monica Bessler
Journal:  Cancer Genet       Date:  2011-12

Review 2.  The biogenesis and regulation of telomerase holoenzymes.

Authors:  Kathleen Collins
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

3.  Specificity and stoichiometry of subunit interactions in the human telomerase holoenzyme assembled in vivo.

Authors:  Emily D Egan; Kathleen Collins
Journal:  Mol Cell Biol       Date:  2010-03-29       Impact factor: 4.272

4.  Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies.

Authors:  M A Trudeau; J M Y Wong
Journal:  Curr Pharmacogenomics Person Med       Date:  2010-03-01

5.  Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita.

Authors:  Judy M Y Wong; Kathleen Collins
Journal:  Genes Dev       Date:  2006-10-02       Impact factor: 11.361

6.  The accumulation and not the specific activity of telomerase ribonucleoprotein determines telomere maintenance deficiency in X-linked dyskeratosis congenita.

Authors:  Xi-Lei Zeng; Naresh R Thumati; Helen B Fleisig; Kyle R Hukezalie; Sharon A Savage; Neelam Giri; Blanche P Alter; Judy M Y Wong
Journal:  Hum Mol Genet       Date:  2011-11-04       Impact factor: 6.150

Review 7.  The many facets of H/ACA ribonucleoproteins.

Authors:  U Thomas Meier
Journal:  Chromosoma       Date:  2005-03-16       Impact factor: 4.316

8.  Investigation of chromosome X inactivation and clinical phenotypes in female carriers of DKC1 mutations.

Authors:  Jialin Xu; Payal P Khincha; Neelam Giri; Blanche P Alter; Sharon A Savage; Judy M Y Wong
Journal:  Am J Hematol       Date:  2016-11-04       Impact factor: 10.047

9.  Clonal hematopoiesis in patients with dyskeratosis congenita.

Authors:  Nieves Perdigones; Juan C Perin; Irene Schiano; Peter Nicholas; Jaclyn A Biegel; Philip J Mason; Daria V Babushok; Monica Bessler
Journal:  Am J Hematol       Date:  2016-10-21       Impact factor: 10.047

Review 10.  Dyskeratosis congenita, stem cells and telomeres.

Authors:  Michael Kirwan; Inderjeet Dokal
Journal:  Biochim Biophys Acta       Date:  2009-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.